Last updated: February 14, 2026
What is NDC 64850-0440?
NDC 64850-0440 refers to a specific drug product listed in the National Drug Code (NDC) directory. It is identified as Trazodone HCl tablets, 50 mg, manufactured by G&W Laboratories Inc. This medication is primarily used for treating depression and is prescribed off-label for insomnia.
Market Size and Sales Data
Historical Sales Trends
- U.S. retail sales of trazodone-based medications have increased significantly over recent years. The market growth aligned with rising mental health concerns and off-label use for sleep disorders.
- In 2022, trazodone sales totaled approximately $500 million, with an annual growth rate of 8% (source: IQVIA).
Market Segmentation
- Prescriber base: Psychiatrists, primary care physicians, sleep disorder clinics.
- Patient base: Adults aged 18-65; older adults also prescribed for sleep.
Competitive Landscape
- Trazodone competes with other antidepressants (SSRIs, SNRIs) and sleep aids (zolpidem, eszopiclone).
- Generic versions dominate the market, owing to low barriers to entry.
Pricing Analysis
Current Price Range
- Average wholesale price (AWP): $0.08 per 50 mg tablet.
- Retail pharmacy cash price: $0.20-$0.30 per tablet.
- Insurance reimbursement: Typically incurs copayments of $10-$20 per prescription (around 30-60 tablets).
Comparison with Market Leaders
- Generic trazodone costs are significantly lower than branded alternatives (e.g., Desyrel or Oleptro).
- The presence of multiple generic suppliers keeps prices competitive.
Regulatory and Patent Status
- No active patents on the generic formulation; expiration dating back to early 2010s.
- FDA approval status: Approved as a generic drug, with widespread market access.
Projected Market Trends and Price Trajectory
Short-term Projections (Next 2 Years)
- Price stability expected due to patent expiration and generic competition.
- Slight downward pressure on prices as new generics enter the market.
- Sales volume likely to increase driven by expanded off-label use for sleep.
Long-term Projections (Next 5 Years)
- Prices are expected to plateau or decline marginally, around $0.05–$0.10 per tablet, as patent cliffs stabilize.
- Market growth will be influenced by shifts in prescribing guidelines and insurance coverage policies.
- Emerging competition from other sleep aids and antidepressants may further pressure pricing.
Key Factors Influencing Market and Prices
- Generic Entry: Continued proliferation reduces prices.
- Prescribing Trends: Increased off-label use for sleep may raise demand.
- Insurance Reimbursement: Changes could impact retail price margins.
- Regulatory Changes: Potential FDA rulings or new formulations might alter market dynamics.
Key Takeaways
- NDC 64850-0440 represents generic trazodone hydrochloride 50 mg tablets, a mature product with broad market penetration.
- The market is characterized by high competition and low pricing, with retail prices below $0.30 per tablet.
- Sales are expected to grow modestly, driven mainly by off-label use, but prices are likely to decline or stabilize in the coming years.
- No major patent protections remain, facilitating generic availability and price competition.
- Market expansion depends on prescribing practices and healthcare policy shifts.
FAQs
1. What is the primary use of trazodone (NDC 64850-0440)?
It is mainly used for depression management. Off-label, it is prescribed for insomnia and anxiety.
2. How does the pricing of this drug compare to branded versions?
Generic trazodone averages $0.08–$0.30 per tablet, significantly lower than branded equivalents, which can be $1.00 or higher per tablet.
3. What factors could influence future pricing?
Market entry of new generics, regulatory changes, prescribing trends, and insurance coverage.
4. Who are the main competitors?
Other antidepressants and sleep aids such as zolpidem, eszopiclone, and branded trazodone formulations.
5. What is the outlook for sales?
Sales are projected to grow modestly due to increased off-label use but remain under pressure from generic competition, leading to stable or declining retail prices.
References
- IQVIA. (2022). Medication Sales Data.
- FDA. (2023). Drug Product Approvals and Patents.
- GoodRx. (2023). Trazodone Pricing and Market Trends.
- SSR Health. (2022). Generic Drug Market Analysis.
- Healthcare Financial Management Association (HFMA). (2023). Insurance Reimbursement Trends.
